DISC MEDICINE INC. - COMMON STOCK

57,45

24-января-25 15:45:00

15 мин. задержка

Акции

+0,46

+0,81%

Сегодняшний диапазон

56,54 - 57,74

ISIN

N/A

Источник

NASDAQ

Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants

22 янв 2025 20:35:43 Источник Nasdaq GlobeNewswire
Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

21 янв 2025 15:01:00 Источник Nasdaq GlobeNewswire
Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission

21 янв 2025 06:45:00 Источник Nasdaq GlobeNewswire
Disc Medicine to Host Conference Call on Type C Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)

20 янв 2025 18:00:00 Источник Nasdaq GlobeNewswire
Disc Medicine Reports Inducement Grant under Nasdaq Listing Rule 5635(C)(4)

17 янв 2025 15:00:00 Источник Nasdaq GlobeNewswire
Disc Medicine Highlights Recent Achievements Across Hematology Portfolio and Key Business Objectives and Milestones for 2025

10 янв 2025 08:00:00 Источник Nasdaq GlobeNewswire
Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting

09 дек 2024 11:00:00 Источник Nasdaq GlobeNewswire
Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th American Society of Hematology (ASH) Annual Meeting

08 дек 2024 19:00:00 Источник Nasdaq GlobeNewswire
Disc Medicine to Participate in Upcoming Investor Conferences

13 ноя 2024 07:30:00 Источник Nasdaq GlobeNewswire
Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update

12 ноя 2024 07:00:00 Источник Nasdaq GlobeNewswire
Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.

08 ноя 2024 07:30:00 Источник Nasdaq GlobeNewswire
Disc Medicine Announces Multiple Presentations Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting

05 ноя 2024 08:00:00 Источник Nasdaq GlobeNewswire
Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval

04 ноя 2024 06:50:00 Источник Nasdaq GlobeNewswire
Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)

01 ноя 2024 15:01:00 Источник Nasdaq GlobeNewswire
Disc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney Week

25 окт 2024 12:00:00 Источник Nasdaq GlobeNewswire
Disc Medicine Appoints Seasoned Industry Executive Rahul Kaushik, Ph.D. as Chief Technical Officer

23 окт 2024 07:00:00 Источник Nasdaq GlobeNewswire
Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney Week

11 окт 2024 07:00:00 Источник Nasdaq GlobeNewswire
Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory Officer

19 сен 2024 07:30:00 Источник Nasdaq GlobeNewswire
Disc Medicine to Participate in Upcoming Investor Conferences

30 авг 2024 07:00:00 Источник Nasdaq GlobeNewswire
Disc Medicine Reports Second Quarter 2024 Financial Results and Provides Business Update

08 авг 2024 07:00:01 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.